Finance leaders struggle to determine generative AI’s costs and benefits, but there are suggestions on how to tackle the problem.

ResMed Inc . (NYSE:RMD) reported its financial results for the second quarter of fiscal year 2025, exceeding analysts' expectations with an earnings per share (EPS) of $2.43, surpassing the forecasted ...